Bavarian Nordic GmbH

Bavarian Nordic is a vaccine-focused biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need.

The company's pipeline targets cancer and infectious diseases and includes ten development programs. In oncology, the company's lead program is PROSTVAC®, a therapeutic vaccine candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial and is being developed under a collaboration agreement with the National Cancer Institute. In infectious diseases, the company's lead program is IMVAMUNE®, a third-generation smallpox vaccine candidate that is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government.

Details


Adresse:
Bavarian Nordic GmbH

Fraunhoferstrasse 13
82152 Martinsried
Deutschland
Arbeitsgebiet:
Sonstige Tätigkeitsfelder
Expansion:
national
Mitarbeiteranzahl:
51-500
Gründungsjahr:
1994